Table 6.
Cluster statistics related to relevant clinical, demographic and genetic data, including treatment use at baseline. Ward`s Euclidean method, Kruskal- Wallis and χ2 test, p < 0.05. Strong sensitization defined as sIgE to respective allergen of > 17.51 kU/L (classes 4–6)
| Feature | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | p value |
|---|---|---|---|---|---|
| No of patients | N = 58 | N = 87 | N = 138 | N = 64 | |
| Strong sensitization to house dust mite (sIgE d1)—No | 18 (31.03%) | 40 (45.98%) | 73 (52.90%) | 31 (48.44%) | < 0.05 |
| Strong sensitization to house dust mite (sIgE d1)—Yes | 40 (68.97%) | 47 (54.02%) | 65 (47.10%) | 33 (51.56%) | < 0.05 |
| Mean (STD) | Mean (STD) | Mean (STD) | Mean (STD) | ||
| % FEV1 predicted at baseline | 0.89 (0.20) | 0.96 (0.13) | 0.82 (0.17) | 0.88 (0.15) | < 0.001 |
| % MEF50 predicted at baseline | 0.92 (0.22) | 1.03 (0.19) | 0.79 (0.22) | 0.84 (0.24) | < 0.001 |
| FENO at baseline (ppb) | 21.5 (23.61) | 17.23 (16.15) | 23.07 (23.14) | 18.59 (13.38) | |
| Age (yrs) | 11.79 (3.39) | 10.16 (3.82) | 9.98 (3.84) | 9.61 (3.64) | < 0.01 |
| Height (cm) | 153.05 (17.78) | 143.9 (19.11) | 143.86 (21.12) | 142.23 (21.24) | < 0.05 |
| Disease duration (yrs) | 5.72 (3.43) | 5.08 (3.84) | 4.12 (3.8) | 3.45 (3.11) | < 0.001 |
| Total IgE (kIU/L) | 686.34 (744.36) | 421.95 (578.5) | 653.9 (1164.19) | 484.79 (516.04) | |
| Eosinophil absolute count (Dunger) | 419.99 (284.96) | 418.71 (347.17) | 380.16 (305.29) | 377.22 (349.65) | |
| Neutrophil blood count (%) | 49.72 (11.26) | 50.79 (13.18) | 49.57 (12.82) | 51.99 (12.96) | |
| hsCRP (mg/L) | 2.58 (6.31) | 4.02 (14.45) | 3.11 (7.52) | 2.57 (3.72) | |
| Platelets (× 109/L) | 291.09 (86.54) | 278.68 (108.14) | 283.72 (105.47) | 257.7 (105.31) | |
| ICS medium and high doses use from 2nd to 3rd visit, N (%) | 30 (51.72%) | 32 (36.78%) | 51 (36.96%) | 38 (59.38%) | < 0.05 |
| SABA use from 2nd to 3rd visit, N (%) | 7 (12.07%) | 6 (6.90%) | 4 (2.90%) | 27 (42.19%) | < 0.001 |
| BMI percentile 0–5, N(%) | 0 (0) | 3 (3.45) | 4 (2.9) | 3 (4.69) | |
| BMI percentile 5–85, N(%) | 47 (81.03) | 53 (60.92) | 94 (68.11) | 46 (71.88) | |
| BMI percentile > 85, N(%) | 11 (18.87) | 31 (35.63) | 40 (28.99) | 15 (23.43) | |
| Gene_rs37973—GG | 13 (22.41%) | 13 (14.94%) | 15 (10.87%) | 12 (18.75%) | < 0.05 |
| Gene_rs37973—GA | 18 (31.03%) | 48 (55.17%) | 70 (50.72%) | 34 (53.12%) | < 0.05 |
| Gene_rs37973—AA | 27 (46.55%) | 26 (29.89%) | 53 (38.41%) | 18 (28.12%) | < 0.05 |